134 related articles for article (PubMed ID: 31516154)
1. Erythema Gyratum Repens Associated With Diffuse B-cell Lymphoma-Report of A Rare Case.
Rao AG; Farheen SS; Amit K; Reddy UD; Aparna K; Kranthi J; Hukkani R
Indian J Dermatol; 2019; 64(4):338. PubMed ID: 31516154
[TBL] [Abstract][Full Text] [Related]
2. [Atypical erythema gyratum repens secondary to bronchogenic carcinoma].
Loske KD; Ragunath M; Sunderkötter C; Metze D
J Dtsch Dermatol Ges; 2003 Mar; 1(3):216-8. PubMed ID: 16285498
[TBL] [Abstract][Full Text] [Related]
3. Erythema gyratum repens unassociated with underlying malignancy.
Kawakami T; Saito R
J Dermatol; 1995 Aug; 22(8):587-9. PubMed ID: 7560457
[TBL] [Abstract][Full Text] [Related]
4. [Subacute cutaneous lupus gyratus repens].
Hochedez P; Vasseur E; Staroz F; Morelon S; Roudier Pujol C; Saiag P
Ann Dermatol Venereol; 2001 Mar; 128(3 Pt 1):244-6. PubMed ID: 11319389
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic Inflammatory Arthritis.
Rast F; Parperis K; Amar S; Al-Charakh M
Cureus; 2018 May; 10(5):e2663. PubMed ID: 30042914
[TBL] [Abstract][Full Text] [Related]
6. [An association of paraneoplastic syndromes in a patient].
Penven K; Verneuil L; Dompmartin A; Louvet S; Leroy D
Ann Dermatol Venereol; 2002; 129(8-9):1042-5. PubMed ID: 12442104
[TBL] [Abstract][Full Text] [Related]
7. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
8. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under
Gutsch J; Werthmann PG; Rosenwald A; Kienle GS
Anticancer Res; 2018 Sep; 38(9):5363-5369. PubMed ID: 30194190
[TBL] [Abstract][Full Text] [Related]
9. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
10. Erythema gyratum repens in a case of resolving psoriasis.
Bryan ME; Lienhart K; Smoller BR; Johnson SM
J Drugs Dermatol; 2003 Jun; 2(3):315-7. PubMed ID: 12848115
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
12. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
13. THERAPY-RELATED T/MYELOID MIXED PHENOTYPE ACUTE LEUKEMIA IN A PATIENT TREATED WITH CHEMOTHERAPY FOR CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMA.
Roberts E; Oncale M; Safah H; Schmieg J
J La State Med Soc; 2016; 168(1):16-20. PubMed ID: 26986862
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Erythema Gyratum Repens Associated With Esophageal Carcinoma.
Matta A
Cureus; 2020 Aug; 12(8):e9971. PubMed ID: 32983674
[TBL] [Abstract][Full Text] [Related]
17. Erythema gyratum repens: a paraneoplastic eruption.
Boyd AS; Neldner KH; Menter A
J Am Acad Dermatol; 1992 May; 26(5 Pt 1):757-62. PubMed ID: 1583177
[TBL] [Abstract][Full Text] [Related]
18. Erythema gyratum repens.
Eubanks LE; McBurney E; Reed R
Am J Med Sci; 2001 May; 321(5):302-5. PubMed ID: 11370793
[TBL] [Abstract][Full Text] [Related]
19. Erythema Gyratum Repens in Long-Term Smoker.
Sauvageau AP; Mojeski J; Fiorica TW; Miller CC
Case Rep Dermatol; 2019; 11(3):268-272. PubMed ID: 31762739
[TBL] [Abstract][Full Text] [Related]
20. Erythema gyratum repens: another case of a rare disorder but no new insight into pathogenesis.
Rojo Sánchez S; Suárez Fernández R; de Eusebio Murillo E; López Bran E; Sanchez de Paz F; Robledo Aguilar A
Dermatology; 1996; 193(4):336-7. PubMed ID: 8993962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
